Baird upgraded McKesson (NYSE:MCK) to outperform from neutral on Thursday, citing the updates the medical distributor gave ...

McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...

Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S.

An arm of health care giant McKesson will pay $448,578 in back wages and interest as part of an agreement with the U.S.

Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...

Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99, in midday ...

In a report released today, Eric Coldwell from Robert W. Baird upgraded McKesson (MCK – Research Report) to a Buy, with a price target of $688.00. Eric Coldwell’s rating is based on McKesson’s ability ...

The health care giant agreed to pay $448,000 in back wages to resolve hiring discrimination allegations at a DFW facility.

McKesson Corp (MCK) reports a 21% revenue increase and raises fiscal 2025 EPS guidance amid strategic expansions and ...

McKesson Medical-Surgical Inc. entered into an agreement with the Labor Department on Monday resolving employment ...

McKesson Medical-Surgical Inc. entered into an agreement with the Labor Department on Monday resolving employment ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson’s Investor Relatio ...